News

Published on 13 May 2022 on Zacks via Yahoo Finance

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia


Article preview image

Editas Medicine, Inc. EDIT announced that the FDA has granted Orphan Drug designation to its investigational gene-editing medicine, EDIT-301, for the treatment of beta thalassemia, a devastating disease that leads to severe anemia, organ failure and premature death.

The Orphan Drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes one that affects fewer than 200,000 individuals in the United States. The designation also includes incentives, including financial aid for clinical testing, and seven-year marketing exclusivity in the event of regulatory approval.

Per the company, the Orphan Drug tag for EDIT-301 for treating beta thalassemia underlines the urgent need for new treatment options for the given patient population.

NASDAQ.EYPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By...

One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - they ...

Simply Wall St. via Yahoo Finance 9 Mar 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePo...

Insider Monkey via Yahoo Finance 8 Mar 2024

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

Total Net Revenue: Increased to $14.0 million in Q4 2023 from $10.5 million in Q4 2022.Net Produc...

GuruFocus.com via Yahoo Finance 7 Mar 2024

EyePoint Pharmaceuticals appoints new Chief Medical Officer

EyePoint Pharmaceuticals appoints new Chief Medical Officer

Investing.com 4 Mar 2024

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares

On January 26, 2024, David Jones, SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc ...

GuruFocus.com via Yahoo Finance 28 Jan 2024

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 71% Above Its Share...

Key Insights The projected fair value for EyePoint Pharmaceuticals is US$38.94 based on 2 Stage F...

Simply Wall St. via Yahoo Finance 14 Jan 2024

EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), a specialty pharmaceutical company, focuses on develo...

GuruFocus.com via Yahoo Finance 11 Jan 2024

What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling You

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders would be excited to see that the share ...

Simply Wall St. via Yahoo Finance 18 Dec 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders t...

Simply Wall St. via Yahoo Finance 13 Dec 2023

Institutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43%...

Key Insights Institutions' substantial holdings in EyePoint Pharmaceuticals implies that they hav...

Simply Wall St. via Yahoo Finance 11 Dec 2023